Drugs / PF-05231023
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01923389 | Sep → Dec 2013 | type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01673178 | Oct 2012 → Aug 2013 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01396187 | Jul 2011 → May 2012 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01285518 | Feb → Jul 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05231023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01923389 ↗ |
| Modality | Protein / enzyme biologic | “a long-acting fibroblast growth factor 21 (FGF21) analogue” PMID 28573777 ↗ Jul 2017 |
| Route | Intravenous | “0.5 mg QD IV x 1 day” NCT01285518 ↗ |